Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.VentureBeat • 05/27/26
MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder CancerZacks Investment Research • 05/25/26
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?Zacks Investment Research • 05/22/26
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.Barrons • 05/22/26
Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In CancerInvestors Business Daily • 05/22/26
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder CancerBusiness Wire • 05/22/26
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal CancerBusiness Wire • 05/21/26
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer StudyZacks Investment Research • 05/20/26
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing ClaimsGlobeNewsWire • 05/20/26
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial CancerBusiness Wire • 05/18/26
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?Zacks Investment Research • 05/13/26
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026Business Wire • 05/12/26
The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and OptexZacks Investment Research • 05/12/26